How Novo Nordisk Built a Moat in Obesity Drugs

In this episode, Lucas and Luna explore how Novo Nordisk turned a diabetes drug into a blockbuster obesity treatment, building a decades-long moat that competitors like Eli Lilly are only now beginning to challenge. They trace the company's strategic bet on GLP-1 science in the 1990s, the manufacturing investments that created a supply advantage, and the intellectual property wall protecting semaglutide until the early 2030s. Specific numbers include the compound annual growth rate of Wegovy sales and the capacity expansion at Novo's Kalundborg facility. Lucas shares a clinical trial data point on cardiovascular outcomes, and Luna questions whether the moat can survive patent cliffs and newer oral therapies. The conversation is grounded in the current market landscape as of June 2026, with a focus on competitive dynamics and strategic durability. #NovoNordisk #GLP1 #ObesityDrugs #Semaglutide #Wegovy #Ozempic #Moat #CompetitiveAdvantage #Pharmaceuticals #EliLilly #Mounjaro #Zepbound #Biotech #DrugPricing #BusinessStrategy #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo